Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.57 |
| ▸ | BLM | P54132 | 2/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28677794 | 0.89 | GRIA2 (0.55) | SLC7A5KDM4EALOX15HSD17B10ALDH1A1 | |
| SCHEMBL28677792 | 0.89 | GRIA2 (0.55) | SLC7A5KDM4EALOX15HSD17B10ALDH1A1 | |
| SCHEMBL2679928 | 0.86 | KDM4E (0.66) | SLC7A5KDM4EALOX15HSD17B10ALDH1A1 | |
| SCHEMBL4140820 | 0.86 | KDM4E (0.66) | SLC7A5KDM4EALOX15HSD17B10ALDH1A1 | |
| SCHEMBL1527634 | 0.84 | KDM4E (0.56) | SLC7A5KDM4EALOX15HSD17B10ALDH1A1 | |
| SCHEMBL31189933 | 0.84 | KDM4E (0.56) | SLC7A5KDM4EALOX15HSD17B10ALDH1A1 | |
| SCHEMBL1572565 | 0.84 | KDM4E (0.56) | SLC7A5KDM4EALOX15HSD17B10ALDH1A1 | |
| SCHEMBL722789 | 0.84 | KDM4E (0.56) | SLC7A5KDM4EALOX15HSD17B10ALDH1A1 | |
| SCHEMBL1572564 | 0.84 | KDM4E (0.56) | SLC7A5KDM4EALOX15HSD17B10ALDH1A1 | |
| SCHEMBL3261631 | 0.84 | KMT2A (0.44) | SLC7A5KDM4EALOX15HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6133039-A | In vivo method for determination of oxidative stress | WASHINTON UNIVERSITY (US) | 2000-10-17 | — | — | US | claimed |
| US-6096556-A | NONINVASIVE EVALUATION OF OXIDATION RESISTANCE IN HUMANS; MEASURING THE DISTRIBUTION OF TYROSINE COMPOUNDS IN URINE SAMPLE FROM HUMAN AND COMPARISON TO CONTROL SAMPLE | WASHINGTON UNIVERSITY (US) | 2000-08-01 | — | — | US | claimed |
| EP-4553065-A2 | NOVEL COMPOUNDS FOR TREATING MITOCHONDRIAL DISEASE | KHONDRION IP B.V. (NL) | 2025-05-14 | — | — | EP | disclosed |
| EP-3359521-B1 | NOVEL COMPOUNDS FOR TREATING MITOCHONDRIAL DISEASE | KHONDRION IP B V (NL) | 2025-04-16 | — | — | EP | disclosed |
| US-11530190-B2 | Compounds for treating mitochondrial disease | KHONDRION IP B.V. (NL) | 2022-12-20 | — | — | US | disclosed |
| US-20210024484-A1 | Novel compounds for treating mitochondrial disease | KHONDRION IP B.V. (NL) | 2021-01-28 | — | — | US | disclosed |
| US-10815211-B2 | Compounds for treating mitochondrial disease | KHONDRION IP B.V. (NL) | 2020-10-27 | — | — | US | disclosed |
| US-10161928-B2 | Wellness panel | WELLMETRIS, LLC (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180305328-A1 | Novel compounds for treating mitochondrial disease | KHONDRION IP B.V. (NL) | 2018-10-25 | — | — | US | disclosed |
| US-20170016924-A1 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | UNIVERSITY OF WASHINGTON (US) | 2017-01-19 | — | — | US | disclosed |
| US-20160202272-A1 | WELLNESS PANEL FOR COMPANION ANIMALS | WELLMETRIX, LLC | 2016-07-14 | — | — | US | disclosed |
| WO-2006014628-A1 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | UNIVERSITY OF WASHINGTON (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20030036203-A1 | Method and graphic representation for profiling oxidative stress and cardiovascular risk | KRONOS GROUP, THE | 2003-02-20 | — | — | US | disclosed |
| EP-0931265-B1 | DIAGNOSTIC METHOD FOR ATHEROSCLEROSIS | UNIV WASHINGTON (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6133039-A | In vivo method for determination of oxidative stress | WASHINTON UNIVERSITY (US) | 2000-10-17 | — | — | US | disclosed |
| US-6133039-A | In vivo method for determination of oxidative stress | WASHINTON UNIVERSITY (US) | 2000-10-17 | — | — | US | disclosed |
| US-6096556-A | NONINVASIVE EVALUATION OF OXIDATION RESISTANCE IN HUMANS; MEASURING THE DISTRIBUTION OF TYROSINE COMPOUNDS IN URINE SAMPLE FROM HUMAN AND COMPARISON TO CONTROL SAMPLE | WASHINGTON UNIVERSITY (US) | 2000-08-01 | — | — | US | disclosed |
| US-6096556-A | NONINVASIVE EVALUATION OF OXIDATION RESISTANCE IN HUMANS; MEASURING THE DISTRIBUTION OF TYROSINE COMPOUNDS IN URINE SAMPLE FROM HUMAN AND COMPARISON TO CONTROL SAMPLE | WASHINGTON UNIVERSITY (US) | 2000-08-01 | — | — | US | disclosed |
| WO-1999040443-A1 | METHOD FOR THE DETERMINATION OF OXIDATIVE STRESS | WASHINGTON UNIVERSITY (US) | 1999-08-12 | — | — | WO | disclosed |
| US-5731208-A | DETERMINATION OF PRESENCE OF P-HYDROXYPHENYLACETALDEHYDE-LYSINE | WASHINGTON UNIVERSITY (US) | 1998-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530190-B2 | Compounds for treating mitochondrial disease | TFAM, MFN2, CPT2 | SLC7A5 2024/4885KDM4E 278/4885ALOX15 346/4885 |
| US-20180305328-A1 | Novel compounds for treating mitochondrial disease | TFAM, NDUFAB1, CPT2 | SLC7A5 1974/4885KDM4E 305/4885ALOX15 329/4885 |
| US-10815211-B2 | Compounds for treating mitochondrial disease | TFAM, MFN2, CPT2 | SLC7A5 2024/4885KDM4E 278/4885ALOX15 346/4885 |
| US-20210024484-A1 | Novel compounds for treating mitochondrial disease | TFAM, NDUFAB1, CPT2 | SLC7A5 1974/4885KDM4E 305/4885ALOX15 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.